The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States.
Olena MandrikJames FotheringhamShijie RenJeffrey A TiceRichard H ChapmanMatthew D StevensonSteven D PearsonSerina Herron-SmithFoluso AgboolaPraveen ThokalaPublished in: Clinical journal of the American Society of Nephrology : CJASN (2022)
Compared with their respective standard care arms, belimumab but not voclosporin met willingness-to-pay thresholds of $100,000 per quality-adjusted life year. Despite potential clinical superiority in the informing trials, there remains high uncertainty around the cost-effectiveness of voclosporin.